尼可地尔对经皮冠状动脉介入治疗心肌损伤的影响

目的观察经皮冠状动脉介入治疗（PCI）术前服用尼可地尔对心肌损伤的影响。方法纳入行择期PCI治疗的冠心病患者100例,随机分为尼可地尔组（n=52）和常规治疗组（n=48）。常规治疗组接受冠心病及PCI术常规药物治疗,尼可地尔组在PCI术前接受7天口服尼可地尔（5mg,tid）治疗,并在PCI术前5h加服尼可地尔5mg。比较两组患者PCI术前及术后6h、18h、24h的肌酸激酶同工酶（CK-MB）、肌钙蛋白I（cTnI）水平的变化。结果两组患者在PCI术前cTnI和CK-MB水平无差异（P〉0.05）;PCI术后6h、18h、24h,尼可地尔组cTnI和CK-MB水平均低于常规治疗组,差异均有统计学意义（P〈0.05）。结论冠心病患者择期PCI术前使用尼可地尔,对PCI术造成的心肌损伤有一定保护作用。

Influence of nicorandil on myocardial injury treated with percutaneous coronary intervention

Objective To observe the influence of nicorandil taken before percutaneous coronary intervention （ PCI ） on myocardial injury. Methods The patients （ n =100） ） treated with selective PCI were randomly divided into nicorandil group （ n =52） ） and routine group （ n =48 ） . The routine group was given routine medications for coronary heart disease （ CHD ） and PCI, and nicorandil group was treated with nicorandil （ 5 mg three times a day ） for 7 days before PCI and added 5 mg 5 hours before PCI. The level changes of creatine kinase MB （ CK-MB ） and cardiac troponin I （ cTnI ） were compared between two groups before PCI and 6 hours, 18 hours and 24 hours after PCI. Results Before PCI there was no difference in the levels of cTnI and CKMB between two groups （ P 0.05 ） . The levels of cTnI and CK-MB were lower in nicorandil group than those in routine group 6 hours, 18 hours and 24 hours after PCI （ P 0.05 ） . Conclusion The usage of nicorandil before PCI in CHD patients can prevent myocardial injury induced by PCI.